|
Eric Dobmeier joined Seattle Genetics in March 2002. He manages the company's business development, legal, corporate communications, strategic marketing and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the worldwide license agreement with Genentech on SGN-40, the in-license of SGN-33 from PDL BioPharma and ADC collaborations with CuraGen, Progenics, Bayer, MedImmune and Agensys. He has also participated in raising over $200 million in equity financing for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman White & McAuliffe, where he represented technology companies in connection with public and private financings, mergers & acquisitions and corporate partnering transactions. Mr. Dobmeier holds a law degree from Boalt Hall School of Law, University of California, Berkeley and an undergraduate degree from Princeton University. | 